Alberta Investment Management Corp Decreases Stake in Natera, Inc. (NASDAQ:NTRA)

Alberta Investment Management Corp trimmed its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 99.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,981 shares of the medical research company's stock after selling 5,011,459 shares during the period. Alberta Investment Management Corp's holdings in Natera were worth $4,904,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Global Retirement Partners LLC boosted its position in Natera by 55.0% in the 4th quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock valued at $69,000 after buying an additional 154 shares during the period. Convergence Investment Partners LLC boosted its position in Natera by 41.1% in the 4th quarter. Convergence Investment Partners LLC now owns 2,757 shares of the medical research company's stock valued at $436,000 after buying an additional 803 shares during the period. CIBC Asset Management Inc boosted its position in Natera by 5.3% in the 4th quarter. CIBC Asset Management Inc now owns 3,663 shares of the medical research company's stock valued at $580,000 after buying an additional 186 shares during the period. State of New Jersey Common Pension Fund D boosted its position in Natera by 0.8% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 43,584 shares of the medical research company's stock valued at $6,899,000 after buying an additional 343 shares during the period. Finally, Capital Performance Advisors LLP boosted its position in Natera by 66.8% in the 4th quarter. Capital Performance Advisors LLP now owns 1,655 shares of the medical research company's stock valued at $262,000 after buying an additional 663 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research report on Monday, November 18th. Barclays began coverage on shares of Natera in a research report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price for the company. Robert W. Baird increased their target price on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Finally, Craig Hallum increased their target price on shares of Natera from $121.00 to $157.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $170.94.

Natera Stock Performance

Shares of NASDAQ:NTRA traded down $6.29 during midday trading on Friday, reaching $161.90. The company's stock had a trading volume of 834,814 shares, compared to its average volume of 1,319,258. The firm has a market capitalization of $21.37 billion, a PE ratio of -91.89 and a beta of 1.66. Natera, Inc. has a twelve month low of $69.74 and a twelve month high of $183.00. The stock has a fifty day moving average of $168.06 and a 200 day moving average of $144.78. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roelof Botha sold 87,473 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares in the company, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock worth $49,741,699 over the last 90 days. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.